GATA3 and primary cutaneous T-cell non-Hodgkin lymphoma: GATA-3 expression by immunohistochemistry (Fig. 1C) was examined in limited-stage CTCL patients without LCT (mean follow-up 8.0 years, IQR: 3.8–10.4 years), and minimal GATA-3 expression observed (Fig. 1C).